Analysts Set BioAge Labs, Inc. (NASDAQ:BIOA) Price Target at $19.00

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have been assigned an average recommendation of “Hold” from the three analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and two have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $19.00.

A number of equities analysts have issued reports on BIOA shares. Citigroup lifted their price target on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a research report on Tuesday, February 3rd. Piper Sandler started coverage on BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, January 27th. Finally, Morgan Stanley set a $23.00 price objective on shares of BioAge Labs in a report on Wednesday, February 4th.

Insider Buying and Selling

In other BioAge Labs news, CFO Dov A. Md Goldstein sold 27,000 shares of the business’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total value of $531,900.00. Following the transaction, the chief financial officer owned 22,408 shares of the company’s stock, valued at approximately $441,437.60. The trade was a 54.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul D. Rubin sold 7,433 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $18.75, for a total value of $139,368.75. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 354,437 shares of company stock worth $5,813,228. 20.82% of the stock is owned by company insiders.

Institutional Trading of BioAge Labs

Hedge funds have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. bought a new position in BioAge Labs in the 2nd quarter worth approximately $206,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of BioAge Labs during the second quarter worth $27,000. Stonepine Capital Management LLC raised its stake in shares of BioAge Labs by 202.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after purchasing an additional 101,085 shares during the period. Intech Investment Management LLC purchased a new stake in BioAge Labs during the 2nd quarter worth about $60,000. Finally, Strs Ohio boosted its stake in BioAge Labs by 26.4% in the 4th quarter. Strs Ohio now owns 22,500 shares of the company’s stock worth $298,000 after purchasing an additional 4,700 shares during the period.

BioAge Labs Price Performance

NASDAQ:BIOA opened at $20.51 on Wednesday. BioAge Labs has a one year low of $2.88 and a one year high of $24.00. The company has a market cap of $735.28 million, a PE ratio of -13.49 and a beta of 1.42. The firm has a 50-day moving average of $17.36 and a 200-day moving average of $10.30.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.